Human trials
It works through amylin, a natural satiety hormone, along a pathway separate from GLP-1.
Ideal for: People seeking support with satiety and appetite control.
- Studied for longer-lasting appetite control
- Studied in combination with other peptides for weight management
- Support for glucose control
- Studied to help maintain weight during menopause
What science says
In combination (CagriSema 2.4/2.4 mg), Novo Nordisk’s REDEFINE program (Phase 2 and 3) recorded weight reductions of 15% to 24%, in studies conducted in the United States, Canada, Europe, and Asia.
Presentation: 5 mg
Under FDA review
Combined with semaglutide as CagriSema, Novo Nordisk submitted it to the FDA in December 2025. A decision is expected in late 2026.